In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Trends in Mid-sized European Licensing

Executive Summary

Mid-sized European drug firms have traditionally spent considerably more on in-licensing than they've received from licensing out their products to other partners. But over the past two years, we've detected a dramatic shift in the ratio of dollars spent versus received in alliances.

You may also be interested in...



Trends in Mid-sized European Licensing

On balance, do mid-sized European players receive more licensing dollars from out-licensing than they spend on in-licensing?

Coronavirus Update: Hardest Hit US States Will Test Moderna’s Vaccine

A round-up of developments in the COVID-19 vaccine field from Moderna, Fosun, Merck & Co and Medicago and more.

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

SC100339

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel